CombiMatrix and Pathology, Inc. Form Partnership to Market and Distribute Prenatal Tests

CombiMatrix and Pathology, Inc. Form Partnership to Market and Distribute
Prenatal Tests

Pathology, Inc. Will Market Chromosomal Microarray for Products of Conception
Testing Market in Nevada, California, Key Midwest Metropolitan Areas

IRVINE, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for cancer and developmental disorders, today announced that it has
entered into a strategic partnership with Pathology, Inc. whereby Pathology,
Inc. will market and distribute CombiMatrix chromosomal microarray tests for
the Products of Conception (POC) testing market in designated geographic
areas. The POC testing market is a subset of the overall prenatal testing
market.

The two-year agreement gives Pathology, Inc. the exclusive right to market or
distribute the microarray tests on behalf of CombiMatrix in the states of
California and Nevada and the St. Louis and Chicago metropolitan areas.
Pathology, Inc. is a full-service, independent Women's Health laboratory based
in Torrance, California.

POC testing allows OB/GYN physicians and other women's health clinicians to
better determine if there is a genetic cause behind a miscarriage or multiple
events. As in other areas of prenatal genetic analysis, microarray testing is
believed by many to be the coming standard of care as it identifies a greater
number of possible genetic abnormalities more accurately than traditional
methods.

"This agreement allows us to better serve the POC market, a very important
area of specialty for our physician customers and their patients," said Vicki
DiFrancesco, President and CEO of Pathology, Inc. "Our commercial team, along
with operational and analytical support of CombiMatrix, will result in
broadening the use and acceptance of chromosomal microarray testing as a
better solution. We believe this partnership will prove to be a beneficial
expansion of services and customer access for both of our companies."

CombiMatrix President and CEO R. Judd Jessup noted that the agreement with
Pathology, Inc. enables CombiMatrix to broaden its geographic reach and expand
its access to the Women's Health market.

"Working closely with Pathology, Inc. allows us to immediately expand our
marketing efforts in the prenatal market for POC testing throughout important
areas like California and Nevada and densely populated metropolitan areas like
St. Louis and Chicago," Jessup said. "Furthermore, this will improve our speed
of access to Pathology, Inc.'s established customer base of OB/GYNs. Finally,
we believe this agreement offers CombiMatrix and Pathology, Inc. the
opportunity to educate the pathologists in their network about the advantages
of using the POC test compared to the historic, traditional standard of
karyotyping in the prenatal market."

The agreement calls for both companies to participate in sales force training
and market development activities and indicates that Pathology, Inc. will
generate a minimum amount of tests each quarter in order to maintain the
exclusive arrangement.

About Pathology, Inc.

Pathology, Inc. is a full-service provider of anatomic and clinical pathology
testing services, with a 30-year foundation in the Women's Health market. With
expertise in molecular and digital pathology, the Company has built a solid
reputation for quality and customer service with clients that include OB/Gyns,
dermatologists, urologists, gastroenterologists, and family practitioners, as
well as surgicenters, endoscopy centers, hospitals, and independent
laboratories. Pathology, Inc. is located at three separate facilities; its
Torrance headquarters, a second facility in Templeton, CA (Central Coast
Clinical Laboratories) and a third laboratory in Monrovia, CA. All three
facilities are CLIA certified and CAP accredited. Pathology, Inc.'s
pathologists, through its association with Affiliated Pathologists Medical
Group (APMG), are all board certified and have a variety of multi-specialty
interests and expertise, as well as extensive cumulative experience in
outpatient pathology. Pathology, Inc. has provided pathology services to
physician offices and pathologists for over 25 years.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets.The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis.CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies.CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals.Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not limited to,
statements regarding projected results of operations and management's future
business, operational and strategic plans, momentum of our pre-natal and
pediatric businesses, test menu expansion, services and reports development
and attracting greater prenatal genetic screening business.These
forward-looking statements are not guarantees of future results and are
subject to risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in any
forward-looking statement.The risks and uncertainties referred to above
include, but are not limited to:our ability to successfully expand the base
of our customers and strategic partners, add to the menu of our diagnostic
tests in both of our primary markets, develop and introduce new tests and
related reports, optimize the reimbursements received for our testing
services, and increase operating margins by improving overall productivity and
expanding sales volumes; our ability to successfully accelerate sales,
steadily increase the size of our customer rosters in both developmental
medicine and oncology; lack of growth in the developmental markets; our
ability to attract and retain a qualified sales force; rapid technological
change in our markets; changes in demand for our future products; the ability
of microarray technology to become the standard of care; legislative,
regulatory and competitive developments; general economic conditions; and
various other factors.Further information on potential factors that could
affect our financial results is included in our Annual Report on Form 10-K,
Quarterly Reports of Form 10-Q, and in other filings with the Securities and
Exchange Commission.We undertake no obligation to revise or update publicly
any forward-looking statements for any reason, except as required by law.

CONTACT: Company Contact:   
         R. Judd Jessup    
         President & CEO, CombiMatrix Corporation 
         Tel (949) 753-0624    

         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com

CombiMatrix Corporation
 
Press spacebar to pause and continue. Press esc to stop.